John Louis DIENER;Jiaping GAO;Rick Jerome SCHIEBINGER
发明人:
John Louis DIENER,Jiaping GAO,Rick Jerome SCHIEBINGER
申请号：
US16407813
公开号：
US20200101137A1
申请日:
2019.05.09
申请国别(地区):
US
年份:
2020
代理人:
摘要：
The invention relates to the identification of new therapeutic methods for the FGF21 polypeptide or protein, or mutants, variants, and fusions thereof, for instance, in treating metabolic diseases associated defects in insulin signaling (e.g. insulin receptor mutation disorders (INSR disorders) and/or autoimmune insulin receptor disorders (Type B insulin Resistance)), defects in insulin production such as type 1 diabetes mellitus, mixed dyslipidemia, nonalcoholic fatty liver disease (NAFLD), and other metabolic disorders, and various lipodystrophies such as HIV-HAART induced partial-lipodystrophy, and in reducing the mortality and morbidity of critically ill patients.
